INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm

IRVINE, Calif.--()--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Ligand Pharmaceuticals Incorporated (“Ligand” or the “Company”) (Nasdaq: LGND) concerning possible violations of federal securities laws.

If you purchased shares of Ligand and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

The investigation centers on whether Ligand and certain of its officers and/or directors violated federal securities laws. On November 9, 2016, Ligand announced that it would not be able to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 and that it was reviewing a potential restatement. On November 14, 2016, the Company announced that it would restate financial statements for the quarters ended September 30, 2015; December 31, 2015; March 31, 2016; and June 30, 2016, due to a material error. Ligand also disclosed that its management determined that the Company did not maintain effective controls over the accuracy and presentation of accounting for income taxes related to complex transactions.

If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Khang & Khang LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

Contacts

Khang & Khang LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com